Ipsen

Ipsen is the global pharmaceutical group which is engaged in production and promotion of medicines of specialized medical care; aggregate turnover of group in 2015 exceeded 1.4 billion euros.

Ipsen sells more than 20 medicines more than in 115 countries of the world and has direct business presence more than in 30 countries.

The field of activity of the company covers development of solutions for oncology, neurology and endocrinology (adult and children's). In a portfolio of key therapeutic products of the company - drugs for treatment of the patients having a prostate cancer, bladder cancer and patients with neuroendocrine tumors.

At the same time, Ipsen is widely provided in the field of primary medical care. The division of research and development of Ipsen is concentrated on creation of the innovation and differentiated technology platforms, peptides and toxins, and located in the heart of the leading biotechnology and medicobiological clusters (Les Ulis/Paris-Saclay, France; Slough/Oxford, Great Britain; Cambridge, USA). In 2015 total expenses of Research and Development of division of Ipsen made nearly 193 million euros.

The staff of Group totals more than 4600 employees worldwide. Shares of Ipsen are traded in segment A on the Euronext Paris stock exchange (the exchange code: IPN, ISIN code: FR0010259150) also have the right to participate in the Service de Règlement Différé (SRD) program. The group is included into Consolidation of the French Exchanges, index 120. Ipsen implemented the program of the American depositary receipt (ADR) of the Sponsored Level I which works at the American security market under the character of IPSEY.